

11-25-05

CASE HA0794 NP  
*[Handwritten signature]*



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304409920US  
Express Mail Label Number

November 23, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BISACCHI ET AL.

APPLICATION NO: 10/775,443

CONFIRMATION NO. 9406

FILED: FEBRUARY 10, 2004

FOR: BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE  
PROTEASE INHIBITORS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
Jing G. Sun, Ph.D.  
Agent for Applicants  
Reg. No. 45,914

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-3791  
Date: November 23, 2005

12/08/2005 JBALINAN 00000047 193880 10775443

01 FC:1806 180.00 DA

**FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10**

EV304409920US  
Express Mail Label Number

November 23, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BISACCHI ET AL.

APPLICATION NO: 10/775,443

CONFIRMATION NO. 9406

FILED: FEBRUARY 10, 2004

FOR: BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE  
PROTEASE INHIBITORS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT**

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

  
Jing G. Sun, Ph.D.  
Agent for Applicants  
Reg. No. 45,914

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-3791  
Date: November 23, 2005



PTO/SB/08B (8/03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PT

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet

of

COMPLETE IF KNOWN	
Application Number	10/775443
Filing Date	02/10/2004
First Named Inventor	GREGORY BISACCHI
Art Unit	1625
Examiner Name	AULAKH, CHARANJIT
Attorney Docket Number	HA0794 NP

## NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant